Market Cap 234.11M
Revenue (ttm) 22.60M
Net Income (ttm) -86.62M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -383.27%
Debt to Equity Ratio 0.00
Volume 44,960
Avg Vol 130,486
Day's Range N/A - N/A
Shares Out 55.74M
Stochastic %K 26%
Beta 3.04
Analysts Strong Sell
Price Target $11.25

Latest News on FHTX

Foghorn Therapeutics to Participate in the BMO Oncology Summit

Oct 1, 2024, 7:00 AM EDT - 8 months ago

Foghorn Therapeutics to Participate in the BMO Oncology Summit


Foghorn Therapeutics: Ifs, Buts, And Clinical Holds

Aug 16, 2023, 5:08 PM EDT - 1 year ago

Foghorn Therapeutics: Ifs, Buts, And Clinical Holds


Foghorn Therapeutics Provides an Update on FHD-609

Apr 24, 2023, 7:00 AM EDT - 2 years ago

Foghorn Therapeutics Provides an Update on FHD-609